US 11,858,939 B2
Hetero-halo inhibitors of histone deacetylase
Martin R. Jefson, Stonington, CT (US); John A. Lowe, III, Stonington, CT (US); Fabian Dey, Basel (CH); Andreas Bergmann, Gauting (DE); Andreas Schoop, Grafrath (DE); and Nathan Oliver Fuller, Arlington, MA (US)
Assigned to Alkermes, Inc., Waltham, MA (US)
Filed by Alkermes, Inc., Waltham, MA (US)
Filed on Dec. 28, 2020, as Appl. No. 17/134,875.
Application 17/134,875 is a continuation of application No. 16/726,990, filed on Dec. 26, 2019, granted, now 10,919,902, issued on Feb. 16, 2021.
Application 16/726,990 is a continuation of application No. 15/741,657, abandoned, previously published as PCT/US2016/040957, filed on Jul. 5, 2016.
Claims priority of provisional application 62/188,857, filed on Jul. 6, 2015.
Prior Publication US 2021/0277007 A1, Sep. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 487/04 (2006.01); A61K 31/13 (2006.01); A61K 31/167 (2006.01); A61K 31/27 (2006.01); A61K 31/435 (2006.01); A61K 31/44 (2006.01); A61K 31/444 (2006.01); C07D 403/12 (2006.01); C07D 401/14 (2006.01); C07D 309/14 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 207/06 (2006.01); C07D 513/04 (2006.01); C07D 417/12 (2006.01); C07D 413/14 (2006.01); A61K 31/437 (2006.01); A61K 31/4985 (2006.01); A61K 31/351 (2006.01); A61K 31/4433 (2006.01); C07D 409/12 (2006.01); A61K 31/506 (2006.01); C07D 491/107 (2006.01); C07D 487/10 (2006.01); A61K 31/4439 (2006.01); C07D 417/14 (2006.01); A61K 31/4155 (2006.01); A61K 31/55 (2006.01); A61K 31/496 (2006.01); A61K 31/427 (2006.01); A61K 31/4965 (2006.01); A61K 31/445 (2006.01); A61K 31/50 (2006.01); A61K 31/4192 (2006.01); A61K 31/415 (2006.01); A61K 31/5377 (2006.01); A61K 31/40 (2006.01); A61K 31/426 (2006.01); A61K 45/06 (2006.01); A61K 31/505 (2006.01); A61K 31/421 (2006.01); C07D 471/10 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 31/13 (2013.01); A61K 31/167 (2013.01); A61K 31/27 (2013.01); A61K 31/351 (2013.01); A61K 31/40 (2013.01); A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/4192 (2013.01); A61K 31/421 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/435 (2013.01); A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 31/444 (2013.01); A61K 31/445 (2013.01); A61K 31/4433 (2013.01); A61K 31/4439 (2013.01); A61K 31/496 (2013.01); A61K 31/4965 (2013.01); A61K 31/4985 (2013.01); A61K 31/50 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); C07D 207/06 (2013.01); C07D 309/14 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/10 (2013.01); C07D 487/10 (2013.01); C07D 491/107 (2013.01); C07D 513/04 (2013.01)] 1 Claim
 
1. A compound having the formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.